Abstract
Insulin-like growth factor 1 (IGF-1) plasma level was assayed in 60 breast cancer patients undergoing six courses of adjuvant chemotherapy. The only observed variation was a slight decrease (10%) in IGF-1 concentrations, assayed before treatment, between the first and the second courses of chemotherapy. During chemotherapy courses, there were no statistically significant variations in IGF-1. These results suggest that chemotherapy, unlike the specific hormonal treatments tamoxifen and somatostatin, certainly does not act via a decrease in plasma IGF-1.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Peyrat, JP., Révillion, F. & Bonneterre, J. Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy. Br J Cancer 77, 1669–1671 (1998). https://doi.org/10.1038/bjc.1998.274
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.274
This article is cited by
-
Adiposity as a risk determinant for postmenopausal breast cancer
International Journal of Obesity (2000)
